Cystatin C and eGFR_CKD-EPI-CysC: novel biomarkers for renal impairment diagnosis and two-year progression-free survival in multiple myeloma

References

• Renal Impairment of Multiple Myeloma Collaborative Study Group. Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma. Chin J Intern Med. 2017;56(11):871–875.
   PubMedGoogle Scholar
• Chen J, Liu H, Li L, et al. Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function. J Clin Lab Anal. 2019;33(5):e22888.
   PubMed Web of Science ®Google Scholar
• Yadav P, Cook M, Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis (Basel). 2016;1(4):241–257. doi:10.1159/000442511.
   PubMed Web of Science ®Google Scholar
• Sharma R, Jain A, Jandial A, et al. Lack of renal recovery predicts poor survival in patients of multiple myeloma with renal impairment. Clin Lymphoma Myeloma Leuk. 2022;22(8):626–634. doi:10.1016/j.clml.2022.04.013.
   PubMed Web of Science ®Google Scholar
• Pasala S, Carmody JB. How to use serum creatinine, cystatin C and GFR. Arch Dis Child Educ Pract Ed. 2017;102(1):37–43. doi:10.1136/archdischild-2016-311062.
   PubMed Web of Science ®Google Scholar
• Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294–1304. doi:10.1001/jama.2019.14745.
   PubMed Web of Science ®Google Scholar
• Delanaye P, Souvignet M, Dubourg L, et al. Measurement of inulin: development. Ann Biol Clin (Paris). 2011;69(3):273–284. doi:10.1684/abc.2011.0580.
   PubMed Web of Science ®Google Scholar
• Delanaye P. Glomerular filtration rate estimation and measurement: the quest for precision. Nephrol Ther. 2018;14(Suppl 1): s 59–S66. doi:10.1016/j.nephro.2018.02.005.
   Google Scholar
• Maillard N, Delanaye P, Mariat C. Exploration of renal glomerular function: estimation of glomerular filtration rate. Nephrol Ther. 2015;11(1):54–67. doi:10.1016/j.nephro.2015.01.002.
   PubMed Web of Science ®Google Scholar
• Tsai CK, Yeh CM, Hsu TL, et al. Underweight as a risk factor of mortality in patients with newly diagnosed multiple myeloma. Support Care Cancer. 2021;29(7):3991–3999. doi:10.1007/s00520-020-05849-4.
   PubMed Web of Science ®Google Scholar
• Ferguson TW, Komenda P, Tangri N. Cystatin C AS A biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015;24(3):295–300. doi:10.1097/MNH.0000000000000115 26066476
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254. doi:10.7326/0003-4819-145-4-200608150-00004.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006.
   PubMed Web of Science ®Google Scholar
• Guan C, Liang M, Liu R, et al. Assessment of creatinine and cystatin C-based eGFR equations in chinese older adults with chronic kidney disease. Int Urol Nephrol. 2018;50(12):2229–2238. doi:10.1007/s11255-018-1909-7.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–2972. doi:10.1182/blood-2007-10-078022.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi:10.1200/JCO.2005.04.242.
   PubMed Web of Science ®Google Scholar
• Grzasko N, Morawska M, Hus M. Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk. 2015;15(4):187–198. doi:10.1016/j.clml.2014.09.012.
   PubMed Web of Science ®Google Scholar
• Pandey, Vikas Kumar, Mazumdar, Prajit, Prasad, Manohar Lal, Mani,. Study of serum cystatin C and serum creatinine in different stages of chronic kidney disease patients. J Assoc Physicians India 2022; 70(4):11–12.
   Google Scholar
• Dimopoulos MA, Kastritis E, Michalis E, et al. The international scoring system (ISS) for multiple myeloma remains a robust prognostic tool independently of patients’ renal function. Ann Oncol. 2012;23(3):722–729. doi:10.1093/annonc/mdr276.
   PubMed Web of Science ®Google Scholar
• Qin X, Xu Y, An G, et al. The impact of renal function on prognostic value of β2-microglobulin of ISS stage system in multiple myeloma patients-Clinical data analysis of 666 patients in a single center. Zhonghua Xue Ye Xue Za Zhi. 2015;36(5):393–397.
   PubMedGoogle Scholar
• Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5(3):e296–e296. doi:10.1038/bcj.2015.20.
   PubMedGoogle Scholar